Archive for the ‘medicine’ Category

« Older Entries

DARPA (US Defense Advanced Research Projects Agency), nanoparticles, and your traumatized brain

Friday, May 10th, 2013

According to the May 10, 2013 news item on Nanowerk,

DARPA, the U.S. Defense Advanced Research Projects Agency, has awarded $6 million to a team of researchers to develop nanotechnology therapies for the treatment of traumatic brain injury and associated infections.

Led by Professor Michael J. Sailor, Ph.D., from the University of California San Diego [UC San Diego], the award brings together a multi-disciplinary team of renowned experts in laboratory research, translational investigation and clinical medicine, including Erkki Ruoslahti, M.D., Ph.D. of Sanford-Burnham Medical Research Institute, Sangeeta N. Bhatia, M.D., Ph.D. of Massachusetts Institute of Technology and Clark C. Chen, M.D., Ph.D. of UC San Diego School of Medicine.

Ballistics injuries that penetrate the skull have amounted to 18 percent of battlefield wounds sustained by men and women who served in the campaigns in Iraq and Afghanistan, according to the most recent estimate from the Joint Theater Trauma Registry, a compilation of data collected during Operation Iraqi Freedom and Operation Enduring Freedom.

“A major contributor to the mortality associated with a penetrating brain injury is the elevated risk of intracranial infection,” said Chen, a neurosurgeon with UC San Diego Health System, noting that projectiles drive contaminated foreign materials into neural tissue.

The May 9, 2013 UC San Diego news release by Susan Brown, which originated the news item, describes the reasons why DARPA wants to use nanoparticles in therapies for people suffering from traumatic brain injury,

Under normal conditions, the brain is protected from infection by a physiological system called the blood-brain barrier. “Unfortunately, those same natural defense mechanisms make it difficult to get antibiotics to the brain once an infection has taken hold,” said Chen, associate professor and vice-chair of research in the Division of Neurosurgery at UC San Diego School of Medicine.

DARPA hopes to meet these challenges with nanotechnology. The agency awarded this grant under its In Vivo Nanoplatforms for Therapeutics program to construct nanoparticles that can find and treat infections and other damage associated with traumatic brain injuries.

“Our approach is focused on porous nanoparticles that contain highly effective therapeutics on the inside and targeting molecules on the outside,” said Sailor, the UC San Diego materials chemist who leads the team. “When injected into the blood stream, we have found that these silicon-based particles can target certain tissues very effectively.”

Several types of nanoparticles have already been approved for clinical use in patients, but none for treatment of trauma or diseases in the brain. This is due in part to the inability of nanoparticle formulations to cross the blood-brain barrier and reach their intended targets.

“Poor penetration into tissues limits the application of nanoparticles to the treatment of many types of diseases,” said Ruoslahti, distinguished professor at Sanford-Burnham and partner in the research. “We are trying to overcome this limitation using targeting molecules that activate tissue-specific transport pathways to deliver nanoparticles.”

There is another major hurdle for treating brain injuries (from the news release),

Treating brain infections is becoming more difficult as drug-resistant strains of viruses and bacteria have emerged. Because drug-resistant strains mutate and evolve rapidly, researchers must constantly adjust their approach to treatment.

In an attempt to hit this moving target, the team is making their systems modular, so they can be reconfigured “on-the-fly” with the latest therapeutic advances.

Nanocomplexes that contain genetic material known as short interfering RNA, or siRNA, developed by Bhatia’s research group at MIT, will be key to this aspect of the team’s approach.

“The function of this type of RNA is that it specifically intereferes with processes in a diseased cell. The advantage of RNA therapies are that they can be quickly and easily modified when a new disease target emerges,” said Bhatia, a bioengineering professor at MIT and partner in the research.

But effective delivery of siRNA-based therapeutics in the body has proven to be a challenge because the negative charge and chemical structure of naked siRNA makes it very unstable in the body and it has difficulty crossing into diseased cells. To solve these problems, Bhatia has developed nanoparticles that form a protective coating around siRNA.

“The nanocomplexes we are developing shield the negative charge of RNA and protect it from nucleases that would normally destroy it. Adding Erkki’s tissue homing and cell-penetrating peptides allows the nanocomplex to transport deep into tissue and enter the diseased cells,” she said.

Bhatia has previously used the cell-penetrating nanocomplex to deliver siRNA to a tumor cell and shut down its protein production machinery. Although her group’s effort has focused on cancer, the team is now going after two other hard-to-treat cell types: drug-resistant bacteria and inflammatory cells in the brain.

“The work proposed by this multi-disciplinary team should provide new tools to mitigate the debilitating effects of penetrating brain injuries and offer our warfighters the best chance of meaningful recovery,” Chen said. [emphasis mine]

BTW, the term ‘warfighters’ is new to me; are we replacing the word ‘soldier’?

Returning to the matter at hand, I found DARPA’s In Vivo Nanoplatforms for Therapeutics program which is described this way on its home page,

Disease limits soldier readiness and creates healthcare costs and logistics burdens. Diagnosing and treating disease faster can help limit its impact. [emphasis mine] Current technologies and products for diagnosing disease are principally relegated to in vitro (in the lab) medical devices, which are often expensive, bulky and fragile.

DARPA’s In Vivo Nanoplatforms (IVN) program seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease.

The IVN Diagnostics (IVN:Dx) program effort aims to develop a generalized in vivo platform that provides continuous physiological monitoring for the warfighter. [emphasis mine] Specifically, IVN:Dx will investigate technologies that may provide:

  • Implantable nanoplatforms using bio-compatible and nontoxic materials
  • In vivo sensing of small and large molecules of biological interest
  • Multiplexed detection of analytes at clinically relevant concentrations
  • External interrogation of the nanoplatform free from any implanted communications electronics
  • Complete system demonstration in a large animal

The IVN Therapeutics (IVN:Tx) program effort will seek unobtrusive nanoplatforms for rapidly treating disease in warfighters.

(I see DARPA is using both soldier and warfighter’.)

This team is not the only one wishing to deliver drug therapies in a targeted fashion to the brain. My Feb. 19, 2013 posting mentioned Chad Mirkin (Northwestern University) and his team’s efforts with spherical nucleic acids (SNAs), from the posting,

Potential applications include using SNAs to carry nucleic acid-based therapeutics to the brain for the treatment of glioblastoma, the most aggressive form of brain cancer, as well as other neurological disorders such as Alzheimer’s and Parkinson’s diseases. Mirkin is aggressively pursuing treatments for such diseases with Alexander H. Stegh, an assistant professor of neurology at Northwestern’s Feinberg School of Medicine. (originally excerpted from this the Feb. 15, 2013 news release on EurekAlert)

Coincidentally, Mirkin has just been named ‘Chemistry World Entrepreneur of the Year’ by the UK’s Royal Society of Chemistry, from the May 10, 2013 news item on Nanowerk,

Northwestern University scientist Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has been named 2013 Chemistry World Entrepreneur of the Year by the Royal Society of Chemistry (RSC). The award recognizes an individual’s contribution to the commercialization of research.

The RSC is honoring Mirkin for his invention of spherical nucleic acids (SNAs), new globular forms of DNA and RNA. These structures form the basis for more than 300 products commercialized by licensees of the technology.

I’m never quite sure what to make of researchers who receive public funding then patent and license the results of that research.

Getting back to soldiers/warfighters, I’m glad to see this research being pursued. Years ago, a physician mentioned to me that soldiers in Iraq were surviving injuries that would have killed them in previous conflicts. The problem is that the same protective gear which insulates soldiers against many injuries makes them vulnerable to abusive head trauma (same principle as ‘shaken baby syndrome’). For example, imagine having a high velocity bullet hit your helmet. You’re protected from the bullet but the impact shakes your head so violently, your brain is injured.

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,
Posted in medicine, military, nanotechnology | No Comments »

Growing new brain cells for implants

Thursday, May 9th, 2013

The dream is that one day this research will allow doctors to replace damaged or destroyed brain cells. According to the May 7, 2013 news release on EurekAlert,

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC [University of California] San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson’s disease, epilepsy, and possibly even Alzheimer’s disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

“We think this one type of cell may be useful in treating several types of neurodevelopmental and neurodegenerative disorders in a targeted way,” said Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF [University of California San Francisco] and co-lead author on the paper.

The May 7, 2013 University of California San Francisco news release by Jeffrey Norris, which originated the release on EurekAlert, provides more detail about the work,

The researchers generated and transplanted a type of human nerve-cell progenitor called the medial ganglionic eminence (MGE) cell, in experiments described in the May 2 edition of Cell Stem Cell. Development of these human MGE cells within the mouse brain mimics what occurs in human development, they said.

…

To generate MGE cells in the lab, the researchers reliably directed the differentiation of human pluripotent stem cells — either human embryonic stem cells or induced pluripotent stem cells derived from human skin. These two kinds of stem cells have virtually unlimited potential to become any human cell type. When transplanted into a strain of mice that does not reject human tissue, the human MGE-like cells survived within the rodent forebrain, integrated into the brain by forming connections with rodent nerve cells, and matured into specialized subtypes of interneurons

The researchers are investigating applications other than brain cell replacement or repair (from the UCSF news release),

Previously, UCSF researchers led by Allan Basbaum, PhD, chair of anatomy at UCSF, have used mouse MGE cell transplantation into the mouse spinal cord to reduce neuropathic pain, a surprising application outside the brain. Kriegstein, Nicholas and colleagues now are exploring the use of human MGE cells in mouse models of neuropathic pain and spasticity, Parkinson’s disease and epilepsy.

“The hope is that we can deliver these cells to various places within the nervous system that have been overactive and that they will functionally integrate and provide regulated inhibition,” Nicholas said.

The researchers also plan to develop MGE cells from induced pluripotent stem cells derived from skin cells of individuals with autism, epilepsy, schizophrenia and Alzheimer’s disease, in order to investigate how the development and function of interneurons might become abnormal — creating a lab-dish model of disease.

There is at least one hurdle to be overcome (from the UCSF news release),

One mystery and challenge to both the clinical and pre-clinical study of human MGE cells is that they develop at a slower, human pace, reflecting an “intrinsic clock”. In fast-developing mice, the human MGE-like cells still took seven to nine months to form interneuron subtypes that normally are present near birth.

“If we could accelerate the clock in human cells, then that would be very encouraging for various applications,” Kriegstein said.

Here’s a link to and a citation for the researchers’ paper,

Functional Maturation of hPSC-Derived Forebrain Interneurons Requires an Extended Timeline and Mimics Human Neural Development by Cory R. Nicholas, Jiadong Chen, Yunshuo Tang, Derek G. Southwell, Nadine Chalmers, Daniel Vogt, Christine M. Arnold, Ying-Jiun J. Chen, Edouard G. Stanley, Andrew G. Elefanty, Yoshiki Sasai, Arturo Alvarez-Buylla, John L.R. Rubenstein, Arnold R. Kriegstein. Cell Stem Cell, Volume 12, Issue 5, 573-586, 2 May 2013

Copyright © 2013 Elsevier Inc. All rights reserved.
10.1016/j.stem.2013.04.005

This research put in me in mind of my Mar. 15, 2013 posting titled, Growing a tooth—as an adult, when I featured research at King’s College London where scientists had successfully used mouse stem cells to  grow teeth in adult mice. The researchers hope to one day be able to do the same in humans.

Tags: , , , , , , , , , , , , , , , , , , , , , ,
Posted in human enhancement, medicine | No Comments »

Nanosilver resistance

Wednesday, May 8th, 2013

Researchers at Australia’s University of New South Wales (UNSW) have published a study where they claim that bacteria have develop resistance to nanosilver, a product used widely for its antibacterial properties. From the May 8, 2013 news item on ScienceDaily,

Researchers from UNSW have cautioned that more work is needed to understand how micro-organisms respond to the disinfecting properties of silver nano-particles, increasingly used in consumer goods, and for medical and environmental applications.

Although nanosilver has effective antimicrobial properties against certain pathogens, overexposure to silver nano-particles can cause other potentially harmful organisms to rapidly adapt and flourish, a UNSW study reveals.

The May 8, 2013 UNSW news release, which originated the news item, notes,

“We found an important natural ability of a widely occurring bacteria to adapt quite rapidly to the antimicrobial action of nanosilver. This is the first unambiguous evidence of this induced adaptation,” says co-author Dr Cindy Gunawan, from the UNSW School of Chemical Engineering.

Using an experimental culture, UNSW researchers observed that nanosilver was effective in suppressing a targeted bacteria (Escherichia coli), but that its presence initiated the unexpected emergence, adaptation and abnormally fast growth of another bacteria species (Bacillus).

The news release mentions some of the implications,

The efficacy of nanosilver to suppress certain disease-causing pathogens has been well-documented, and as a result, it has become widely used in medicine to coat bandages and wound dressings. It also has environmental uses in water and air purification systems, and is used in cosmetics and detergents, and as a surface coating for things like toys and tupperware.

But the researchers say this exploitation of nanosilver’s antimicrobial properties have “gained momentum due in part to a lack of evidence for the potential development of resistant microorganisms”.

“Antimicrobial action of nanosilver is not universal and the widespread use of these products should take into consideration the potential for longer-term adverse outcomes,” says Gunawan.

The researchers say these adverse impacts could be more pronounced given the near-ubiquitous nature of the Bacillus bacteria, which originate from airborne spores, and because the resistance trait can potentially be transferred to the genes of other micro-organisms.

“For the medical use of nanosilver, this implies the potential for reduced efficacy and the development of resistant populations in clinical settings,” says co-author Dr Christopher Marquis, a senior lecturer from the UNSW School of Biotechnology and Biomolecular Sciences. [emphasis mine]

I have touched on the issue of resistance and bacteria previously in the context of finding new ways to deal with them in my Don’t kill bacteria, uninvite them posting of Aug. 13, 2012 about developing new materials that resist bacteria and and there’s my mention of Sharklet, a material based on the nanoscale properties of sharkskin and which has potential for use in hospital settings, in my Feb. 10, 2011 posting.

For those who’d like to read about this work from the University of New South Wales, the ScienceDaily news item provides a link to and a citation for the paper which has been published in Small. This paper is behind a paywall and the publisher (Wiley Online Library), puzzingly and in comparison to other publishers, has made the paper hard to find.

Tags: , , , , , , , , ,
Posted in medicine, nanotechnology, risk | No Comments »

University of Alberta (Canada) student nanorobotics team demonstrates potential medical technology in competitiion

Monday, May 6th, 2013

A University of Alberta (Canada) nanorobotics team has entered its nanobot system into the International Mobile Micro/nanorobotics Competition in Karlsruhe, Germany, as part of the ICRA Robot Challenges at the IEEE (Institute of Electrical and Electronics Engineers) International Conference on Robotics and Automation (ICRA) being held May 6 – 10, 2013 in Karlsruhe, Germany. From the May 6, 2013 news item on Nanowerk,

A team of engineering students is putting a twist on robotics, developing a nano-scale robotics system that could lead to new medical therapies.

In less than a year, the U of A team has assembled a working system that manipulates nano-scale ‘robots’. The team uses magnets to manipulate a droplet filled with iron oxide nanoparticles. Barely visible to the naked eye, the droplet measures 400-500 micrometres.

The May 3, 2013 University of Alberta news release by Richard Cairney, which originated the news item, describes the system,

Using a joystick, team members control the robot, making it travel along a specific route, navigate an obstacle course or to push micro-sized objects from one point to another.

The challenge is simple in concept but highly technical and challenging to execute: the team first injects a water droplet with iron oxide nanoparticles into into oil. The droplet holds its shape because it is encased in a surfactant—a soap-like formula that repels water on one side and attracts water on the other.

“It’s like a capsule,” said team member Yang Gao, who is working on her master’s degree in chemical engineering. “It’s a vehicle for the nanoparticles.”

The iron-filled droplet is placed in a playing ‘field’ measuring 2 x 3 millimetres. The team uses four magnets mounted each side of the rectangular field to move the droplet in a figure-8, manoeuvring it through four gates built into the field.

“We use the magnets to pull the droplet,” explains electrical engineering PhD student Remko van den Hurk.

In a second challenge, the team will be required to use the droplet as a bulldozer of sorts, to arrange micro-scale objects that measure 200 x 300 micrometres into a particular order on an even smaller playing field.

The competition has its serious side, these nanobots could one day be used in medical applications.

In the meantime there’s the competition, good luck!

Tags: , , , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

Emory University’s Shuming Nie discusses Iron Man 3 and nanotechnology and researchers develop an injectable nano-network

Monday, May 6th, 2013

I have written about Iron Man 3 before (my May 11, 2012 posting) in the context of its nanotechnology inspirations, specifically, the Extremis Armor. For anyone not familiar with the story, I have a few bits which will bring you up to speed before getting to Shuming Nie’s commentary and some recent research into injectable nano-networks, which seems highly relevant to the Iron Man 3 discourse. First, here’s an excerpt from my May 11, 2012 posting,

In a search for Extremis, I found out that this story reboots the Iron Man mythology by incorporating nanotechnology and alchemy to create a new armor, the Extremis Armor, from the Extremis Armor website (I strongly suggest going to the website and reading the full text which includes a number of illustrative images if you find this sort of thing interesting),

When a bio-tech weapon of mass destruction was unleashed, Tony Stark threw himself onto the bleeding edge between science and alchemy, combining nanotechnology and his Iron Man armor.  The result, which debuted in Iron Man, Vol. IV, issue 5, was the Extremis Armor, Model XXXII, Mark I, which made him the most powerful hero in the world–but not without a price.

…

There were two key parts to this Extremis-enhanced suit.  The first part is the golden Undersheath, the protective interface between Stark’s nervous system and the second chief part, the External Suit Devices (ESDs), a.k.a. the red armor plating.

The Undersheath to the Iron Man suit components was super-compressed and stored in the hollows of Stark’s bones. The sheath material exited through skeletal pores and slid between all cells to self-assemble a new “skin” around him.  This skin provides a complete interface to the Iron Man suit components and can perform numerous other functions. (The process in reverse withdrew the Undersheath back into these specially modified areas of Tony Stark’s bone marrow tissue.)

The Undersheath is a nano-network that incorporates peptide-peptide logic (PPL), a molecular computational system made of superconducting plastic impregnated molecular chains. [my emphasis added for May.6.13 posting]  The PPL handles, among other things: memory, critical logic paths, comparative “truth” tables, automatic response look-up tables, data storage, communication, and external sensing material interface.

The lattice assembly is a stress-compression truss with powered interstitial joints.  This can surround the PPL material and guide it through Stark’s body.  This steerable, motile lattice framework is commanded by the PPL molecule computational mentality.  The metallic component to the lattice is a controlled mimetic artifact that can take on the characteristics of most elements.  Even unusual combinations of behaviors such as extreme hardness and flexibility.

The combination of the two nano-scale materials allows for a very dense non-traditional computer that can change the fabric of its design in very powerful ways. The incorporation of the Undersheath in Stark’s entire nervous system renders reflex-level computer responses to pan-spectrum stimuli.

Anthony Stark’s Bio/Metalo-Mimetic Material concept is a radical departure from the traditional solid-state underpinnings of his prior Iron Man suit designs.  Making use of nano-scale assembly technology, “smart” molecules can be made atom by atom. The design allows for simple computers to be linked into a massive parallel computer that synthesizes human thought protocols.

The External Suit Devices (ESDs), the red armor plates, were made via mega-nano technology that has assembled atoms into large, discreet effectors.  This allows for the plates to be collapsable to very small volumes for easy storage and carried in Stark’s briefcase. The ESDs were commanded by the Undersheath and were self-powered by high-capacity Kasimer plates.  They were equipped with large arrays of nano-fans that allow flight.  Armoring-up was done by drawing the suit to Stark via a vectored repulsor field, just lightly pushing them from different angles.

The armor’s memory-metal technology renders it lightweight and flexible while not in use, but extremely durable when polarized.  The armor was strong, of course, but it could be made even stronger by rerouting repulsor input to reinforce the armor’s mass.

Stark’s skin is now a part of the suit, when engaged.  [emphasis mine] Comfort is relative because the suit rapidly responds to any discomfort, from impacts to high temperatures, from itching to scratching.  The suit’s protocols include semi-autonomy when needed.  Where Stark ends and the suit begins is flexible.  The exact nature of the artificial Extremis Virus is not known (especially because Stark recompiled the dose, then tweaked the nutrients and suspended metals, radically altering Maya Hansen’s [the character Rebecca Hall will reputedly play] formulations).  The effect it has had on Stark’s body is to allow the presence of so much alien material within his body without trauma.

Because of the bio-interface between Tony and the armor, he could utilize the suit to its fullest potential and also instantly access computers and any digital system worldwide at the speed of thought.  He was biologically integrated with his armor, one with it, imbued with unprecedented powers and abilities.  He channeled and processed data, emergency signals, and satellite reconnaissance from every law enforcement, military, and intelligence service in the world–in his head.  He could send electronic signals and make phone calls with his mind.  He could see through satellites.  Plus he had the ability to transmit whatever he saw (from his visual cortex) to other people’s display screens.  The computer’s cybernetic link enables him to operate all of the armor’s functions, as well as providing a remote link to other computers (as Stark is now part of the armor this connection is seamless).  The armor’s system was connected to the global mainframe via StarkTech servers.

I also like this more generalized description of the technology in the Wikipedia essay on Extemis Comics (Note: A link has been removed),

Extremis has been referred to as a “virus” constantly since the story. The verbatim description offered by its inventor Maya Hansen, goes: “…Extremis is a super-soldier solution. It’s a bio-electronics package, fitted into a few billion graphite nanotubes and suspended in a carrier fluid. [emphasis mine] A magic bullet, like the original super-soldier serum—all fitted into a single injection. It hacks the body’s repair center—the part of the brain that keeps a complete blue print of the human body. When we’re injured, we refer to that area of the brain to heal properly. Extremis rewrites the repair center. In the first stage, the body essentially becomes an open wound. The normal human blueprint is being replaced with the Extremis blueprint. The brain is being told the body is wrong. Extremis protocol dictates that the subject be placed on life support and intravenously fed nutrients at this point. For the next two or three days, the patient remains unconscious within a cocoon of scabs. (…) Extremis uses the nutrients and body mass to grow new organs. Better ones…”

A Postmedia movie reviewer, Katherine Monk noted this about the plot in her May 3, 2013 review of Iron Man 3 ,

Apparently, back in the early days of genetic engineering, a brilliant, zit-faced scientist (Guy Pearce) offered Tony a piece of a lucrative patent that had the potential to alter the human body, and even regenerate amputated limbs.

Tony walked away from the offer as well as the pretty girl (Rebecca Hall) who worked for the genetic engineer, but in the opening sequence, we see the technology was successfully developed and tested. It makes people superhuman, but it can also make them spontaneously combust, leaving great craters and human casualties behind.

Now for the video commentary, Dr. Shuming Nie, Biomedical Engineering at Emory University, offers some scientific insight into the science and the fiction of ‘extremis’ as per Iron Man 3 in his YouTube video,

Keeping on the science theme,  researchers at North Carolina State University (NCSU) and other institutions announced an injectable nano-network for diabetics in a May 3, 2013 news release on EurekAlert,

In a promising development for diabetes treatment, researchers have developed a network of nanoscale particles that can be injected into the body and release insulin when blood-sugar levels rise, maintaining normal blood sugar levels for more than a week in animal-based laboratory tests. The work was done by researchers at North Carolina State University, the University of North Carolina at Chapel Hill, the Massachusetts Institute of Technology and Children’s Hospital Boston.

“We’ve created a ‘smart’ system that is injected into the body and responds to changes in blood sugar by releasing insulin, effectively controlling blood-sugar levels,” says Dr. Zhen Gu, lead author of a paper describing the work and an assistant professor in the joint biomedical engineering program at NC State and UNC Chapel Hill. “We’ve tested the technology in mice, and one injection was able to maintain blood sugar levels in the normal range for up to 10 days.”

Here’s how the smart system is achieved,

The new, injectable nano-network is composed of a mixture containing nanoparticles with a solid core of insulin, modified dextran and glucose oxidase enzymes. When the enzymes are exposed to high glucose levels they effectively convert glucose into gluconic acid, which breaks down the modified dextran and releases the insulin. The insulin then brings the glucose levels under control. The gluconic acid and dextran are fully biocompatible and dissolve in the body.

Each of these nanoparticle cores is given either a positively charged or negatively charged biocompatible coating. The positively charged coatings are made of chitosan (a material normally found in shrimp shells), while the negatively charged coatings are made of alginate (a material normally found in seaweed).

When the solution of coated nanoparticles is mixed together, the positively and negatively charged coatings are attracted to each other to form a “nano-network.” Once injected into the subcutaneous layer of the skin, the nano-network holds the nanoparticles together and prevents them from dispersing throughout the body. Both the nano-network and the coatings are porous, allowing blood – and blood sugar – to reach the nanoparticle cores.

“This technology effectively creates a ‘closed-loop’ system that mimics the activity of the pancreas in a healthy patient, releasing insulin in response to glucose level changes,” Gu says. “This has the potential to improve the health and quality of life of diabetes patients.”

For anyone who’s interested in researching further, heres’ a citation for and a link to the paper,

Injectable Nano-Network for Glucose-Mediated Insulin Delivery by Zhen Gu, Alex A. Aimetti, Qun Wang, Tram T. Dang, Yunlong Zhang, Omid Veiseh, Hao Cheng, Robert S. Langer, and Daniel G. Anderson. ACS Nano, Article ASAP DOI: 10.1021/nn400630x Publication Date (Web): May 2, 2013

Copyright © 2013 American Chemical Society

The paper is behind a paywall. Meanwhile, there are discussions about moving these injectable nano-networks into human clinical trials. As Nie notes, Iron Man 3 hints at new medical technologies which will be achievable in the next 10 or so years, although we may have to wait 100 to 150 years for  Extremis armor.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , ,
Posted in biomimcry, medicine, nanotechnology | No Comments »

Watching zinc, iron, and copper molecules real-time as they interact with biomolecules

Friday, May 3rd, 2013

Eventually they’re hoping this work will lead to insights about diabetes and cancer. In the meantime, researchers at RIKEN Center for Life Science Technologies (Japan) have developed a new imaging technique that allows them to observe metal molecules interacting with biomolecules in real-time. From the May 2, 2013 news release on EurekAlert,

Metal elements and molecules interact in the body but visualizing them together has always been a challenge. Researchers from the RIKEN Center for Life Science Technologies in Japan have developed a new molecular imaging technology that enables them to visualize bio-metals and bio-molecules simultaneously in a live mouse. This new technology will enable researchers to study the complex interactions between metal elements and molecules in living organisms.

It’s well known we need zinc, iron, and copper in our bodies for proper functioning. Until now, no one has been able to observe the interaction in real-time, from the RIKEN May 2, 2013 press release (which originated the EurekAlert news release),

In the study, the researchers were able to visualise two radioactive agents injected in a tumor-bearing mouse, as well as an anti-tumor antibody labelled with a PET molecular probe agent, simultaneously in the live mouse.

This new revolutionary technology is expected to offer new insights into the relationships between bio-metal elements and associated bio-molecules, and the roles they play in diseases such as diabetes and cancer.

The researchers had to create a camera capable of visualizing the interactions (from the RIKEN press release),

Dr. Shuichi Enomoto, Dr. Shinji Motomura and colleagues, from the RIKEN Center for Life Science Technologies have developed a gamma-ray imaging camera enabling them to detect the gamma-rays emitted by multiple bio-metal elements in the body and study their behavior.

Their second prototype of the system, called GREI–II and presented today in the Journal of Analytical Atomic Spectrometry, enables them to visualize multiple bio-metal elements more than 10 times faster than before, and to do so simultaneously with positron emission tomography (PET).

You can find the research study here.

For those unfamiliar with RIKEN, here’s more from their About RIKEN page,

RIKEN is Japan’s largest comprehensive research institution renowned for high-quality research in a diverse range of scientific disciplines. Founded in 1917 as a private research foundation in Tokyo, RIKEN has grown rapidly in size and scope, today encompassing a network of world-class research centers and institutes across Japan.

Tags: , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

Dark field imaging and silica nanorattles

Wednesday, May 1st, 2013

According the Apr. 26, 2013 Science China Press news release on EurekAlert, bioimaging and disease diagnosis using gold nanoparticles have not progressed as hoped for due to issues with their biocompatibility and stability in body fluids (I believe there are some translation issues),

In many metal materials, gold nanoparticles have caused concerns [I think 'interest' is closer to what they meant] in the field because of its simple preparation, easy to modify advantages. However, the poor stability in physiological fluids environment and the potential toxicity of gold nanoparticles always restricts its application in the biological field.

TANG Fangqiong and her group from Laboratory of Controllable Preparation and Application of Nanomaterials, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences have been devoted to the controllable preparation of nanomaterials and biological applications. In recent years, they invented a method to fabricate silica nanoparticles with the special rattles-type structure named silica nanorattles (SNs) and developed the nanoparticles as drug delivery system, biological detection and catalytic. Their work, entitled “Dark field imaging of rattle-type silica nanorattles coated gold nanoparticles in vitro and in vivo”, was published in Chinese Science Bulletin 2013, Vol 58(7).

In this paper, the gold nanoparticles were ingeniously hybridized into the hollow cavity of silica nanorattles. Then, a new type silica nanorattles coated gold nanoparticles (Silica nanorattles @ gold nanoparticles, SN @ GNs) was obtained. It has advantage as following, scale preparation, good stability in the physiological environment and reduce gold nanoparticles agglomeration. These particles remained the strong optical scattering of gold nanoparticles and plasma resonance properties which can be used in dark field imaging of cells and animal tissues in vivo … . And more important[,] the silica nanoshells significantly reduced the toxicity of gold nanoparticles in vivo, which increase[d] the maximum tolerated dose to 200 mg/kg.

Above all, TANG group have developed a new type of composite nanoparticles [combining] silica['s] good biocompatibility and the optical properties of gold nanoparticles. It provides a new material and method for the application of nanomaterials in biological imaging and disease diagnosis.

For clarity, I have made a few changes to the text I excerpted from the news release.

Here’s a link to and a citation for the researchers’ paper,

LIU TianLong, TAN LongFei, LIU HuiYu, FU ChangHui, CHEN Dong, and TANG FangQiong. Dark field imaging of rattle-type silica nanorattles coated gold nanoparticles in vitro and in vivo[J]. Chinese Science Bulletin, 2013, 58(7): 531-536.

While the abstract is available in English, you will need to be able to read Chinese for the rest of paper, which appears to be behind a paywall.

Tags: , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

Inhale the drugs for Parkinson’s disease

Wednesday, April 24th, 2013

The news out of Northeastern University’s Dr. Barbara Waszczak’s lab is exciting but it’s a single high point in a larger narrative.  First, here’s the high point described in the Apr. 24, 2013 news item on Azonano,

Researchers at Northeastern University in Boston have developed a gene therapy approach that may one day stop Parkinson’s disease (PD) in it tracks, preventing disease progression and reversing its symptoms. The novelty of the approach lies in the nasal route of administration and nanoparticles containing a gene capable of rescuing dying neurons in the brain.

The Apr. 21, 2013 news release on EurekAlert, which originated the news item, provides some information about Parkinson’s disease,

Parkinson’s is a devastating neurodegenerative disorder caused by the death of dopamine neurons in a key motor area of the brain, the substantia nigra (SN). Loss of these neurons leads to the characteristic tremor and slowed movements of PD, which get increasingly worse with time. Currently, more than 1% of the population over age 60 has PD and approximately 60,000 Americans are newly diagnosed every year. The available drugs on the market for PD mimic or replace the lost dopamine but do not get to the heart of the problem, which is the progressive loss of the dopamine neurons.

Here’s how the disease got its name, from the Wikipedia essay: Parkinson’s disease (Note: Links have been removed),

The disease is named after the English doctor James Parkinson, who published the first detailed description in An Essay on the Shaking Palsy in 1817. Several major organizations promote research and improvement of quality of life of those with the disease and their families. Public awareness campaigns include Parkinson’s disease day (on the birthday of James Parkinson, April 11) and the use of a red tulip as the symbol of the disease. People with parkinsonism who have increased the public’s awareness include Michael J. Fox and Muhammad Ali.

Now for some information about the background work leading up to this new, exciting, high point (from the news release on EurekAlert),

The focus of Dr. Barbara Waszczak’s lab at Northeastern University in Boston is to find a way to harvest the potential of glial cell line-derived neurotrophic factor (GDNF) as a treatment for PD. GDNF is a protein known to nourish dopamine neurons by activating survival and growth-promoting pathways inside the cells. Not surprisingly, GDNF is able to protect dopamine neurons from injury and restore the function of damaged and dying neurons in many animal models of PD. However, the action of GDNF is limited by its inability to cross the blood-brain barrier (BBB), thus requiring direct surgical injection into the brain. To circumvent this problem, Waszczak’s lab is investigating intranasal delivery as a way to bypass the BBB. Their previous work showed that intranasal delivery of GDNF protects dopamine neurons from damage by the neurotoxin, 6-hydroxydopamine (6-OHDA), a standard rat model of PD.

According to the Michael J. Fox Foundation, this research work dates from 2007 (at least), from the Intranasal Delivery of GDNF for Parkinson’s Disease: Next Steps grant page,

FINAL OUTCOME

The results of this Drug Delivery 2008 project confirm and extend the conclusions reached under a previous 2007 Rapid Response Innovation Award. The research team has demonstrated that intranasal administration of GDNF has neuroprotective efficacy in a preclinical model of Parkinson’s disease, that the protein gets into the brain and reaches target structures (the striatum and substantia nigra) within an hour of nasal administration, and that the nasal route causes no apparent toxicity in the nose. Longer term efficacy and toxicology studies will be necessary in other relevant preclinical models before testing can be initiated in humans.

The results of this work strongly supports pursuit of intranasal administration as a promising approach for harvesting the therapeutic potential of GDNF. Such an approach could ultimately provide an effective, non-invasive means of delivering GDNF to the brain for the treatment of Parkinson’s disease.

Here’s the 2013 innovation on intranasal delivery of GDNF therapy (from the news release on EurekAlert),

Taking this work a step further, Brendan Harmon, working in Waszczak’s lab, has adapted the intranasal approach so that cells in the brain can continuously produce GDNF. His work utilized nanoparticles, developed by Copernicus Therapeutics, Inc., which are able to transfect brain cells with an expression plasmid carrying the gene for GDNF (pGDNF). When given intranasally to rats, these pGDNF nanoparticles increase GDNF production throughout the brain for long periods, avoiding the need for frequent re-dosing. Now, in new research presented on April 20 at 12:30 pm during Experimental Biology 2013 in Boston, MA, Harmon reports that intranasal administration of Copernicus’ pGDNF nanoparticles results in GDNF expression sufficient to protect SN dopamine neurons in the 6-OHDA model of PD.

Waszczak and Harmon believe that intranasal delivery of Copernicus’ nanoparticles may provide an effective and non-invasive means of GDNF gene therapy for PD, and an avenue for transporting other gene therapy vectors to the brain. This work, which was funded in part by the Michael J. Fox Foundation for Parkinson’s Research and Northeastern University, has the potential to greatly expand treatment options for PD and many other central nervous system disorders.

For the curious, there’s more about Copernicus Therapeutics at the company website.

Congratulations to Harmon and Waszczak! I imagine the next step will be human clinical trials.

Tags: , , , , , , , , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

Sponging up the toxins in your blood

Monday, April 15th, 2013

It doesn’t sound like these nanosponges are going to help you with your hangover but should you have a snakebite, an E. coli infection or other such pore-forming toxin in your blood, engineers at the University of California at San Diego are working on a solution. From the University of California at San Diego Apr. 14, 2103 news release,

Engineers at the University of California, San Diego have invented a “nanosponge” capable of safely removing a broad class of dangerous toxins from the bloodstream – including toxins produced by MRSA, E. coli, poisonous snakes and bees. These nanosponges, which thus far have been studied in mice, can neutralize “pore-forming toxins,” which destroy cells by poking holes in their cell membranes. Unlike other anti-toxin platforms that need to be custom synthesized for individual toxin type, the nanosponges can absorb different pore-forming toxins regardless of their molecular structures. In a study against alpha-haemolysin toxin from MRSA, pre-innoculation with nanosponges enabled 89 percent of mice to survive lethal doses. Administering nanosponges after the lethal dose led to 44 percent survival.

They’ve produced a video about their work,

I like the fact that this therapy isn’t specific but can be used for different toxins (from the news release),

“This is a new way to remove toxins from the bloodstream,” said Liangfang Zhang, a nanoengineering professor at the UC San Diego Jacobs School of Engineering and the senior author on the study. “Instead of creating specific treatments for individual toxins, we are developing a platform that can neutralize toxins caused by a wide range of pathogens, including MRSA and other antibiotic resistant bacteria,” said Zhang. The work could also lead to non-species-specific therapies for venomous snake bites and bee stings, which would make it more likely that health care providers or at-risk individuals will have life-saving treatments available when they need them most.

Here’s how the nanosponges work (from the news release),

In order to evade the immune system and remain in circulation in the bloodstream, the nanosponges are wrapped in red blood cell membranes. This red blood cell cloaking technology was developed in Liangfang Zhang’s lab at UC San Diego. The researchers previously demonstrated that nanoparticles disguised as red blood cells could be used to deliver cancer-fighting drugs directly to a tumor. …

Red blood cells are one of the primary targets of pore-forming toxins. When a group of toxins all puncture the same cell, forming a pore, uncontrolled ions rush in and the cell dies.

The nanosponges look like red blood cells, and therefore serve as red blood cell decoys that collect the toxins. The nanosponges absorb damaging toxins and divert them away from their cellular targets. The nanosponges had a half-life of 40 hours in the researchers’ experiments in mice. Eventually the liver safely metabolized both the nanosponges and the sequestered toxins, with the liver incurring no discernible damage. [emphasis mine]

It’s reassuring to see that this therapy doesn’t damage as it heals.

For those interested, here’s some technical information about how the nanosponges are created in the laboratory (from the news release),

Each nanosponge has a diameter of approximately 85 nanometers and is made of a biocompatible polymer core wrapped in segments of red blood cells membranes.

Zhang’s team separates the red blood cells from a small sample of blood using a centrifuge and then puts the cells into a solution that causes them to swell and burst, releasing hemoglobin and leaving RBC [red blood cell] skins behind. The skins are then mixed with the ball-shaped nanoparticles until they are coated with a red blood cell membrane.

Just one red blood cell membrane can make thousands of nanosponges, which are 3,000 times smaller than a red blood cell. With a single dose, this army of nanosponges floods the bloodstream, outnumbering red blood cells and intercepting toxins. Based on test-tube experiments, the number of toxins each nanosponge could absorb depended on the toxin. For example, approximately 85 alpha-haemolysin toxin produced by MRSA, 30 stretpolysin-O toxins and 850 melittin monomoers, which are part of bee venom.

In mice, administering nanosponges and alpha-haemolysin toxin simultaneously at a toxin-to-nanosponge ratio of 70:1 neutralized the toxins and caused no discernible damage.

This seems like promising work and, hopefully, they will be testing these nanosponges in human clinical trials soon.

Here’s a link to and a citation for the researchers’ paper,

A biomimetic nanosponge that absorbs pore-forming toxins by Che-Ming J. Hu, Ronnie H. Fang, Jonathan Copp, Brian T. Luk,& Liangfang Zhang. Nature Nanotechnology (2013) doi:10.1038/nnano.2013.54 Published online 14 April 2013

This paper is behind a paywall. (H/T to EurekAlert [Apr. 14, 2013 news release].)

The last time I wrote about nanosponges it was in the context of oil spills in my Apr. 17, 2012 posting.

Tags: , , , , , , , , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

Sanofi BioGENEius Challenge Canada awards national prizes to winners

Tuesday, April 9th, 2013

I last wrote about Sanofi BioGENEius Challenge Canada and its awards in my Feb. 20, 2013 posting on the occasion of the organization’s 20th anniversary in Canada. Today, Apr. 9, 2013, there’s an annoucement that the 2013 Sanofi BioGENEius Challenge Canada prizes were awarded today in Ottawa,

Cutting edge research into an experimental therapy that deploys nano-particles of gold to kill cancer cells earned an Alberta high school student, 16, top national honours today in the 2013 “Sanofi BioGENEius Challenge Canada” (SBCC).

India-born Arjun Nair, 16, a Grade 11 student at Webber Academy, Calgary, was awarded the top prize of $5,000 by a panel of eminent Canadian scientists assembled at the Ottawa headquarters of the National Research Council of Canada (NRC).

His research project, mentored at the University of Calgary, advances an experimental cancer “photothermal therapy” which involves injecting a patient with gold nanoparticles.  The particles accumulate in tumours, forming so-called “nano-bullets” that can be heated to kill cancer cells.

Arjun showed how an antibiotic may overcome defences cancer deploys against the therapy and make the promising treatment more effective.  Arjun’s research, which a panel of expert judges led by Dr. Luis Barreto called “world class Masters or PhD-level quality,” also won a special $1,000 prize awarded to the project with the greatest commercial potential.

There were other winners too,

Eleven brilliant students from nine Canadian regions, all just 16 to 18 years old, took part in the national finals.  They had placed 1st at earlier regional SBCC competitions, conducted between March 21 and April 4.

Celebrating 20 years of inspiring young scientists in Canada, this year’s SBCC involved a total of 208 high school and CEGEP students collaborating on 123 projects, all mentored in professional labs over several months and submitted via the regional competitions.  Since its beginning in Toronto in 1994, some 4,500 young Canadians have competed in the SBCC, an event that has inspired sister BioGENEius competitions in the USA and Australia.

2nd place, $4,000 — British Columbia: Selin Jessa, 17, Grade 12, Dr. Charles Best Secondary School, Coquitlam, won the $4,000 2nd place prize with research into how genetic mutations naturally help some HIV patients escape symptoms.

Arjun and Selin will compete for Canada April 22-23 at the International BioGENEius Challenge, conducted at the annual BIO conference, this year in Chicago.

3rd place, $3,000 — Quebec: Eunice Linh You, 17, Grade 11, Laval Liberty High School, Laval, who investigated how to tailor stem cell treatments for Parkinson’s disease

4th place, $2,000 — Greater Toronto: Lauren Chan, 17, Grade 12, University of Toronto Schools, who described a potential new therapy to reduce the severity of diabetes

5th place, $1,000 — Manitoba: Daniel Huang, 16, Grade 11, St. John’s Ravenscourt School, Winnipeg, who discovered a potential new tactic to fight the world’s deadliest brain cancer

Honorable mention, $500:

Newfoundland, Jared Trask, 18, Kaitlyn Stockley, 17, Grade 12, Holy Spirit High School, Conception Bay West, who, for the second consecutive year, won the Atlantic region competition by proving novel ideas for creating biofuels;

Eastern Ontario, Adamo Young, 16, Grade 11, Lisgar Collegiate Institute, Ottawa, who found that altering its nitrogen supply appears to tame a toxic fungus that ruins billions worth of grain worldwide;

Southwestern Ontario, Melanie Grondin, 17, Shawn Liu, 18, Vincent Massey Secondary School, Windsor, who found a marker in medicine’s quest for the holy grail of leukaemia treatments: limitless supplies of healthy stem cells.

Saskatchewan, Saruul Uuganbayar, 17, Grade 12, Centennial Collegiate, Saskatoon, who invented a molecular therapy for mutated cells with the dream of curing cancer.

Given my interest in nanotechnology, Nair’s project is particularly intriguing,

Aiming to create an effective cancer-killing nano-bullet made of gold

Helping science develop a nano-bullet to defeat cancer is the futuristic vision of Arjun Nair, a 16-year-old Calgary high school student.

These “bullets” are formed by gold nanoparticles that, when injected into a patient, accumulate in cancerous tumours. Using light, the gold nanoparticles rapidly heat up in the tumours, killing only the cancer cells. Known as photothermal therapy (PTT), the idea has shown promise but isn’t that effective because cancer cells fight back, producing heat-shock proteins to protect themselves.

Arjun looked into the use of an antibiotic (17-AAG) to defeat cancer’s defence.

Nanoparticles are less than millionth of the size of grain of sand, making them pretty difficult to make and work with, says Arjun. He spent the last two years working on his idea, including the past year between Simon Trudel’s and David Cramb’s Nanoscience Labs at the University of Calgary [see my interview with Dr. Cramb in my Mar. 8, 2010 posting and he is mentioned here in other postings should you care to search his name].

It’s rare for a high-tech lab to allow a high school student to work with its expensive equipment but Dr. Cramb, Dr. Simon Trudel and Lab Manager, Amy Tekrony provided access and all important mentorship, he says.

“Proof-of-concepts were developed and tested in order to demonstrate the viability of PTT,” says Arjun.  “Moreover, after analyzing the literature a mathematical model was developed to evaluate a theoretical synergetic treatment.”

“I’ve entered science competitions since Grade 5. I really enjoy taking my ideas and making them happen in real life,” says Arjun, who also enjoys debating, sports and volunteer work.

He dreams of doing science in university, perhaps pursuing a career in medical research. One of the best parts of the competition was the great friendships Arjun has made. “I’m part of community of students who love sharing ideas and talking science.”

They make quite a big deal of these awards,

Following the presentation ceremony at the NRC, the students were received by Governor-General David Johnston at Rideau Hall, a distinguished educator prior to his vice-regal appointment.

Dr. Kellie Leitch, Parliamentary Secretary to the Minister of Human Resources Skills Development, keynote speaker at the awards ceremony, said: “It is so important that we have all of our skills and talent at work in Canada and the SBCC offers students a fantastic opportunity to experience science and technology in new ways, hopefully encouraging them toward exciting careers. I want to congratulate the winners, and all of the participants, of this year’s competition and I thank the organizers for all of the work that they have done in supporting young people in science.”

Sanofi Canada President and CEO Jon Fairest, who presented the top national prize, said: “The Sanofi Group is very proud to be founding sponsors of the Sanofi BioGENEIus Challenge Canada (SBCC) and participate in this milestone competition. With its 20-year heritage, the SBCC shows how critical partnerships are to advance science and talent in Canada. From the mentoring provided by dedicated academics, to the support of government and the private sector, the SBCC truly stands out as a model for collaboration. The SBCC and the incredible students who participate inspire us to all think differently about our future and ensure we have a strong foundation in place to create a sustainable healthcare system in Canada.”

The SBCC gives young scientists access to professional labs and academic mentors, encouraging the pursuit of future studies and careers in the country’s fast-growing biotechnology sector.

Each of the students worked for months conducting research and collaborating with university mentors.

It’s not just public officials and Sanofi officials who are paying attention,

The nine final national projects were presented at NRC headquarters Monday April 8 to a panel of eminent Canadian scientists:

  • Dr. Luis Barreto, MD, Chief Judge, Bioscience Education Canada
  • Dr. Roman Szumski, Vice President Research, National Research Council Canada
  • Dr. Paul Lasko, Scientific Director, Institute of Genetics, Canadian Institutes of Health Research
  • Dr. Robert Tsushima, Associate Dean of Research, Faculty of Science, York University
  • Dr. Pierre Meulien, President, Genome Canada
  • Dr. Ron Pearlman, Associate Scientific Director, Gairdner Foundation
  • Dr. Jerome Konecsni, President, Innovation Saskatchewan

On the panel as well: Ms. Janelle Tam, 18, of Waterloo, Ontario, SBCC’s national first-place winner in 2012.

National Awards Presenters, National Research Council Canada, April 9, 2013:

Commercialization Award – Dr. Ron Pearlman, Associate Scientific Director, Gairdner Foundation

5th Place – Dr. Alison Symington, VP, Corporate Development, Ontario Genomics Institute / Genome Canada

4th Place — Dr. Spriros Pagiatakis, Associate Dean, Research & Partnerships, York University

3rd Place – Dr. Alain Beaudet, President, Canadian Institutes of Health Research

2nd Place – John McDougall, President, National Research Council of Canada

1st Place – Jon Fairest, President and CEO, Sanofi Canada

The Canadian competition does not stand alone,

The Sanofi BioGENEius Challenge Canada (SBCC) is a national, biotechnology research competition that encourages high school and CEGEP students to pursue future studies and careers in the exciting field of biotechnology. The initiative is sponsored by Sanofi Pasteur Limited, Sanofi Canada, the National Research Council Canada/ Conseil national de recherches Canada (NRC-CNRC), Canadian Institutes of Health Research/Instituts de recherche en santé du Canada (CIHR-IRSC), York University, Genome Canada and the Government of Canada’s Youth Awareness Program. Canada’s respected Sanofi BioGENEius Challenge Canada has inspired counterpart competitions in the USA and Australia.

For more information, please see Wikipedia (http://bit.ly/11MtXX9), visit sanofibiogeneiuschallenge.ca, and follow us on Facebook or Twitter @BioscienceEdCan

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company’s heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com  or www.sanofipasteur.us

Good luck to Arjun Nair and Selin Jessa when they compete for Canada April 22-23, 2013 at the International BioGENEius Challenge, conducted at the annual BIO conference, in Chicago, Illinois.

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Posted in medicine, nanotechnology | No Comments »

« Older Entries